Clinical Trial Update: FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

View source ↗

Summary

The FOCUS trial evaluating FazaClo (clozapine) for schizophrenia has completed, with weight gain and sialorrhea noted as conditions of interest.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• FazaClo (clozapine)

Snippet

Sponsor: Azur Pharma, Inc | Conditions: Weight Gain, Sialorrhea | Status: COMPLETED